Multivalent Vaccines Targeting Influenza, RSV, SARS-CoV-2, and More
Overview
Combination vaccines targeting multiple respiratory viruses offer a promising strategy to improve vaccination rates and simplify immunization schedules, especially for adults. Despite challenges such as immune interference and formulation complexities, lessons from pediatric combination vaccines provide a valuable framework for developing multivalent respiratory vaccines.
Background
Vaccination has dramatically reduced the burden of many infectious diseases since the first licensed influenza vaccine in 1945. Pediatric combination vaccines have improved vaccine acceptance and timeliness by reducing the number of injections required. Adult vaccination schedules have traditionally been less reliant on combination vaccines due to differing age indications and timing. However, the recent availability of vaccines for influenza, COVID-19, and RSV has renewed interest in developing multivalent vaccines to protect against multiple respiratory pathogens simultaneously.
Data Highlights
A German study demonstrated increasing completion rates of the Hib vaccine series by 12 months with combination vaccines: 13.3% with monovalent vaccines, 17.8% with tetravalent, 27.7% with pentavalent, and 39.1% with hexavalent vaccines. Hexavalent vaccines were also better tolerated, with fewer adverse events compared to multiple separate injections.
Key Findings
Combination vaccines contain multiple immunogens in a single preparation, improving vaccination rates and timeliness, especially in pediatric populations.
Development challenges include physical compatibility of components, immune interference, and potential reduction in immunogenicity due to adjuvant or carrier protein interactions.
Immune dominance and antigen ratio optimization are critical to ensure balanced immune responses in multivalent vaccines.
Adult vaccination has historically lacked urgency for combination vaccines, but the emergence of multiple respiratory vaccines (influenza, COVID-19, RSV) creates a rationale for multivalent respiratory vaccines.
Combination vaccines can reduce needle burden, clinic visits, and administrative workload, potentially improving acceptance and cost-effectiveness.
Clinical trials must demonstrate safety and at least noninferior efficacy compared to individual vaccines for new combination products.
Clinical Implications
Clinicians should anticipate the potential availability of multivalent respiratory vaccines that could simplify adult immunization schedules and improve uptake. Understanding the complexities of combination vaccine development can inform patient counseling and vaccine selection. Monitoring ongoing clinical trial data will be essential to ensure these vaccines meet safety and efficacy standards.
Conclusion
Multivalent vaccines targeting multiple respiratory pathogens represent a promising advancement in vaccinology, leveraging pediatric combination vaccine successes to address adult immunization challenges. Continued research and development are needed to overcome formulation and immunologic hurdles to realize their full public health potential.
References
Invited Perspective, Viruses, Special Collection on Vaccine Sciences -- Multivalent Vaccines Targeting Influenza, Respiratory Syncytial Virus, SARS-CoV-2, and Additional Pathogens
